Capital Impact Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-21,305
| Closed | -$2.04M | – | 124 |
|
|
2021
Q3 | $2.04M | Sell |
21,305
-3,191
| -13% | -$306K | 0.81% | 57 |
|
|
2021
Q2 | $2.38M | Buy |
24,496
+9,759
| +66% | +$950K | 0.77% | 59 |
|
|
2021
Q1 | $1.43M | Sell |
14,737
-7,369
| -33% | -$717K | 0.5% | 73 |
|
|
2020
Q4 | $2.12M | Hold |
22,106
| – | – | 0.52% | 76 |
|
|
2020
Q3 | $2.13M | Hold |
22,106
| – | – | 0.63% | 75 |
|
|
2020
Q2 | $2.7M | Hold |
22,106
| – | – | 0.9% | 42 |
|
|
2020
Q1 | $1.91M | Buy |
22,106
+943
| +4% | +$81.6K | 0.8% | 54 |
|
|
2019
Q4 | $2.28M | Buy |
21,163
+2,614
| +14% | +$281K | 0.8% | 48 |
|
|
2019
Q3 | $1.67M | Sell |
18,549
-2,374
| -11% | -$214K | 0.64% | 100 |
|
|
2019
Q2 | $1.72M | Buy |
+20,923
| New | +$1.72M | 0.63% | 86 |
|